NRx Pharmaceuticals reports a Q2 loss exceeding estimates by $0.09 per share, worsening from a year-ago loss of $0.98.
NRx Pharmaceuticals Inc. (NRXP) reported a second-quarter loss of $0.18 per share, missing the Zacks Consensus Estimate of a $0.09 loss. The adjusted figure reflects non-recurring items excluded from the calculation.
A year earlier, the company posted a loss of $0.98 per share. Revenue also fell short of expectations, though specific figures were not disclosed in the release.
Shares of NRXP showed limited movement in after-hours trading following the announcement.